PolyPid (PYPD) has released an update.
PolyPid Ltd., a biopharma company focused on improving surgical outcomes, has secured $8.1 million through a private placement funding round, aiming to extend its cash runway into Q2 2025. This funding will support the ongoing SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections in abdominal surgeries. Additionally, the company restructured a secured loan agreement, deferring over $2 million in repayments to align with anticipated SHIELD II trial results.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.
